IP Verse

Boehringer Ingelheim Pharma competitive analysis

Latest publications and patents of Boehringer Ingelheim Pharma New

Explore the latest publications and patents granted to Boehringer Ingelheim Pharma, showcasing their recent innovations and technological advancements.

Last updated on: Sep 27, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Boehringer Ingelheim Pharma

EP2397142
Jul 27, 2022Use Of Dpp Iv InhibitorsGranted And Under Opposition
EP2152341
Dec 11, 2019Atomizer, And FilterGranted And Under Opposition
EP2433665
Aug 7, 2019Inhaler And Sieve For An InhalerRevoked
EP1940349
Feb 14, 2018Aerosol Formulation For The Inhalation Of Beta AgonistsOpposition Rejected
EP2119717
Jan 17, 20188-[3-Amino-Piperidin-1-Yl]-Xanthins, Their Production And Utilisation As Dpp Iv InhibitorsNo Opposition Filed Within Time Limit
EP1830843
Nov 7, 2012Indolidone Derivatives For The Treatment Or Prevention Of Fibrotic DiseasesOpposition Rejected
EP2011041840
Feb 24, 2011Atomizing Device, Inhaler And Method For Dispensing A Liquid Formulation -
EP2044967
Apr 8, 2009Atomiser -
EP03084502
Oct 16, 2003Inhalation Kit Comprisung Inhalable Powder Of Tiotropium -

Latest oppositions filed by Boehringer Ingelheim Pharma

Explore patent oppositions filed by Boehringer Ingelheim Pharma against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 2, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP3219328
Human Anti-Il-23 Antibodies, Compositions, Method And UsesJANSSEN BIOTECHMar 17, 2021
EP2634243
Improved Process For The Culturing Of CellsDPXJun 5, 2018
EP2634242
Improved Process For The Culturing Of CellsDPXJan 4, 2018
EP2634250
Improved Process For The Culturing Of CellsDPXJan 4, 2018

Latest patents of Boehringer Ingelheim Pharma opposed by its competitors

Explore Boehringer Ingelheim Pharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 2, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP2397142
Jul 27, 2022Use Of Dpp Iv Inhibitors5
EP2152341
Dec 11, 2019Atomizer, And Filter2
EP2433665
Aug 7, 2019Inhaler And Sieve For An Inhaler1
EP1940349
Feb 14, 2018Aerosol Formulation For The Inhalation Of Beta Agonists1
EP1830843
Nov 7, 2012Indolidone Derivatives For The Treatment Or Prevention Of Fibrotic Diseases1

Latest PTAB cases involving Boehringer Ingelheim Pharma

Discover the latest PTAB cases involving Boehringer Ingelheim Pharma, highlighting their recent legal challenges and patent disputes.

Last updated on: Oct 3, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Boehringer Ingelheim Pharma

IPR2017-02032Aug 31, 2017BOEHRINGER INGELHEIM PHARMACEUTICALSGENENTECHTerminated
IPR2017-02031Aug 31, 2017BOEHRINGER INGELHEIM PHARMACEUTICALSGENENTECHTerminated
IPR2017-02029Aug 31, 2017BOEHRINGER INGELHEIM PHARMACEUTICALSGENENTECHTerminated-Settled
IPR2016-01566Aug 10, 2016MYLAN PHARMACEUTICALSBOEHRINGER INGELHEIM PHARMACEUTICALSInstitution Denied
IPR2016-01565Aug 10, 2016MYLAN PHARMACEUTICALSBOEHRINGER INGELHEIM PHARMACEUTICALSTerminated
IPR2016-01564Aug 10, 2016MYLAN PHARMACEUTICALSBOEHRINGER INGELHEIM PHARMACEUTICALSTerminated
IPR2016-01563Aug 10, 2016MYLAN PHARMACEUTICALSBOEHRINGER INGELHEIM PHARMACEUTICALSTerminated
IPR2015-00418Dec 15, 2014BOEHRINGER INGELHEIM PHARMACEUTICALSBIOGENInstitution Denied
IPR2015-00417Dec 15, 2014BOEHRINGER INGELHEIM PHARMACEUTICALSGENENTECHTerminated-Settled
IPR2015-00415Dec 15, 2014BOEHRINGER INGELHEIM PHARMACEUTICALSGENENTECHTerminated-Settled

Peer Comparison New

IP litigation analysis comparing Boehringer Ingelheim Pharma with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 2, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases FacedStrategy Type
BOEHRINGER INGELHEIM PHARMA BOEHRINGER INGELHEIM3 - - - Highly Aggressive
DPX - 9 - - Non-Active
DSM ASSETS1995 - 15Defensive
PATHEON I - 9 - - Non-Active